Oyster Point Pharma, Inc. OYST
11.17 +11.17
Day range unavailable
52-week range unavailable
Analyst view
Consensus: hold
Hold
Price target (mean) 15.00 +34.3% upside
Now 11.17
- Target (low)
- 11.00
- Target (mean)
- 15.00
- Target (high)
- 22.00
Ratings (-1m) 5 3 buy · 2 hold · 0 sell
- Strong buy0
- Buy3
- Hold2
- Sell0
- Strong sell0
Recommendation trend
- 1 month ago 5
- 2 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.26 | -1.38 – -1.16 | -1.61 | +21.7% | 13.65M | +106.9% | 4 |
| Next quarter | -0.89 | -0.90 – -0.89 | -1.80 | +50.6% | 21.90M | +709.9% | 2 |
| Current year | -6.31 | -6.58 – -6.14 | -3.87 | -63.0% | 27.45M | +11.9% | 4 |
| Next year | -3.19 | -4.53 – -2.50 | -6.31 | +49.4% | 99.15M | +261.2% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2022 | Chardan Capital | Downgrade | Buy | Neutral |
| Nov 8, 2022 | Piper Sandler | Downgrade | Overweight | Neutral |
| Aug 11, 2022 | Chardan Capital | Initiated | — | Buy |
| Jul 18, 2022 | HC Wainwright & Co. | Initiated | — | Buy |
| Nov 9, 2021 | JP Morgan | Downgrade | Overweight | Neutral |
| Nov 25, 2019 | JP Morgan | Initiated | — | Overweight |
| Nov 25, 2019 | Cowen & Co. | Initiated | — | Outperform |
| Nov 25, 2019 | Piper Jaffray | Initiated | — | Overweight |